论文部分内容阅读
许多研究已证实一些降压剂影响血清K~+、Mg~++、尿酸、糖、脂肪和肾素的代谢,因而可以减低或抵消其控制血压的有益作用。因此,在评价新的抗高血压药物时,必须考虑到药物的这些影响。最近几年,钙拮抗剂(Calcium Antagonist,CA)作为高血压起始治疗药物已展现出可喜苗头,有证据表明,用CA治疗高血压可以抑制动脉粥样硬化的发生。最近,Fleckenstein强调了高钙因素的危害及CA的预防作用,提出促成动脉粥样硬化形成的主要危险因素(如年老、糖尿病、高血压、吸烟、维生素D)均能增
Many studies have confirmed that some antihypertensive agents affect the metabolism of serum K ~ +, Mg ~ + +, uric acid, sugar, fat and renin and thus can reduce or counteract their beneficial effects on blood pressure control. Therefore, in evaluating new antihypertensive drugs, these effects of the drug must be taken into account. In recent years, calcium antagonists (Calcium Antagonist, CA) as a starting treatment for hypertension has shown gratifying signs, there is evidence that the treatment of hypertension with CA can inhibit the occurrence of atherosclerosis. Recently, Fleckenstein highlighted the dangers of hypercalcemia and the prophylactic effect of CA, proposing that the major risk factors contributing to atherosclerosis (age, diabetes, hypertension, smoking, vitamin D)